- SEK206.18m
- -SEK60.82m
- SEK26.00m
Brief: Orexo Announces Positive Pharmacokinetic In-Vivo Data For Powder-Based Intranasal Semaglutide Formulation
Brief: Orexo Maintains 2025 Financial Outlook
Brief: Orexo Appoints Friedrich Von Bohlen Und Halbach As Chairman
Brief: Orexo Q1 EBIT SEK -5.2 Million
Brief: Orexo Announces Positive Data For Powder-Based Intranasal Vaccine
Brief: Orexo Sees Positive EBITDA For FY 2025
Brief: Orexo Q4 EBIT SEK -98 Million
Brief: Orexo Converts Future Rights For OX-MPI To Shares In Gesynta Pharma Valued At SEK 19 Mln
Brief: Orexo Announces Positive Topline Data From Clinical Study Of OX640
Brief: Orexo Announces Positive Topline Data From Clinical Study Of OX640 In Subjects With And Without Allergic Rhinitis
Brief: Orexo Announces Positive Topline Results From Clinical Study
Brief: Orexo To Resolve Patent Litigation With Sun In US
Brief: Orexo And Gaia Terminate Partnership For Deprexis
Brief: Orexo AB - Study Is Expected To Cost Sek 11 Million
Brief: Orexo Q3 EBIT SEK -21.7 Million
Brief: Orexo Maintains Guidance For 2024
Brief: Orexo Q2 EBIT SEK -15.8 Million
US FDA declines to approve Orexo's opioid overdose drug (updated)
US FDA declines to approve Orexo's opioid overdose drug